Ocumension Therapeutics Future Growth
Future criteria checks 5/6
Ocumension Therapeutics is forecast to grow earnings and revenue by 101.9% and 39.3% per annum respectively. EPS is expected to grow by 101.8% per annum. Return on equity is forecast to be -0.3% in 3 years.
Key information
101.9%
Earnings growth rate
101.8%
EPS growth rate
| Pharmaceuticals earnings growth | 21.4% |
| Revenue growth rate | 39.3% |
| Future return on equity | -0.3% |
| Analyst coverage | Low |
| Last updated | 17 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,429 | 271 | 167 | N/A | 3 |
| 12/31/2025 | 887 | -51 | 104 | 238 | 3 |
| 12/31/2024 | 470 | -232 | -7 | 73 | 3 |
| 6/30/2024 | 310 | -323 | -467 | -175 | N/A |
| 3/31/2024 | 278 | -351 | -503 | -176 | N/A |
| 12/31/2023 | 246 | -380 | -540 | -178 | N/A |
| 9/30/2023 | 227 | -399 | -561 | -223 | N/A |
| 6/30/2023 | 208 | -418 | -582 | -269 | N/A |
| 3/31/2023 | 184 | -411 | -546 | -235 | N/A |
| 12/31/2022 | 159 | -403 | -511 | -201 | N/A |
| 9/30/2022 | 124 | -393 | -615 | -165 | N/A |
| 6/30/2022 | 90 | -383 | -720 | -129 | N/A |
| 3/31/2022 | 73 | -322 | -791 | -163 | N/A |
| 12/31/2021 | 56 | -260 | -862 | -197 | N/A |
| 9/30/2021 | 44 | -426 | -760 | -232 | N/A |
| 6/30/2021 | 32 | -593 | -659 | -267 | N/A |
| 3/31/2021 | 23 | -1,429 | -588 | -240 | N/A |
| 12/31/2020 | 13 | -2,265 | -517 | -213 | N/A |
| 9/30/2020 | 8 | -2,540 | -407 | -173 | N/A |
| 6/30/2020 | 2 | -2,816 | -297 | -133 | N/A |
| 3/31/2020 | 1 | -2,064 | -203 | -120 | N/A |
| 12/31/2019 | 0 | -1,312 | -109 | -108 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 5DG is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: 5DG is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 5DG is expected to become profitable in the next 3 years.
Revenue vs Market: 5DG's revenue (39.3% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 5DG's revenue (39.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 5DG is forecast to be unprofitable in 3 years.